Impedimed Ltd (ASX: IPD) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Impedimed Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $149.71 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 2.02 billion
Earnings per share -0.006
Dividend per share N/A
Year To Date Return -50.34%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Impedimed Ltd (ASX: IPD)
    Latest News

    Businessman walks through exit door signalling resignation
    Share Market News

    2 ASX All Ords shares tumbling following leadership shakeups

    Investors have reacted to the leadership shakeups announced by the two ASX All Ords shares by hitting the sell button.

    Read more »

    Happy healthcare workers in a labs
    Healthcare Shares

    3 ASX healthcare stocks that have more than doubled in a year

    Shareholders of these ASX healthcare stocks are having a party in 2023.

    Read more »

    A worried man holds his head and look at his computer.
    Share Fallers

    Why Brainchip, Impedimed, Northern Star, and Telix shares are falling today

    It has been a tough time for these ASX shares on Thursday.

    Read more »

    A man looks down with fright as he falls towards the ground.
    Share Fallers

    Why Dusk, Impedimed, Nufarm, and Weebit Nano shares are falling

    Investors have been selling these ASX shares on Friday.

    Read more »

    A woman jumps for joy with a rocket drawn on the wall behind her.
    Healthcare Shares

    Guess which ASX biotech share just rocketed 86% on 'a major validating moment'

    There’s a good reason why this biotech share has almost doubled in value today.

    Read more »

    Three people in a corporate office pour over a tablet, ready to invest.
    Earnings Results

    3 ASX All Ords shares making moves today following earnings, one up 16%

    Helia Group is the standout among these three ASX All Ords stocks today.

    Read more »

    Three rock climbers hang precariously off a steep cliff face, each connected to the other with the higher person holding on and the two below them connected by their arms and rope but not making contact with the cliff face.
    Earnings Results

    3 ASX All Ords shares tumbling lower following full-year results

    These ASX All Ords shares took a bath on Monday following earnings...

    Read more »

    A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
    Healthcare Shares

    Impedimed (ASX:IPD) share price dips following capital raising update

    The company announced the results of its capital raise.

    Read more »

    A doctor in a white coat with a stethoscope around his neck stands in the hallway of a hospital deep in concentration over a tablet device in his hands.
    Healthcare Shares

    What's going on with the Impedimed (ASX:IPD) share price?

    Here's why Impedimed's stock is halted on the ASX.

    Read more »

    Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
    Share Gainers

    The Impedimed (ASX:IPD) share price is up 10% on trial success

    More good news out of the medical technology company's camp today.

    Read more »

    A drawing of a rocket follows a chart up, indicating share price lift
    Share Market News

    Why the Impedimed (ASX:IPD) share price is rocketing 9% today

    Impedimed shares are gaining traction...

    Read more »

    heavy lifting, lifting index, carrying weight, boy lifting dumbbell above his head
    Share Gainers

    Impedimed (ASX:IPD) share price rises with 46% lift in revenues

    Let's take a closer look.

    Read more »

    Frequently Asked Questions

    No, Impedimed does not pay shareholder dividends at this time.

    Impedimed Limited listed on the ASX on 24 October 2007.

    IPD ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Impedimed Ltd

    Impedimed Ltd (ASX: IPD) is a global leader in the design and manufacture of medical devices that use bioimpedance spectroscopy (BIS) technologies in the non-invasive clinical assessment of fluid and tissue composition.

    The company's products are typically used to assess and monitor lymphedema and heart failure, as well as to measure patients' tissue composition and fluid status. They also have general health applications in weight management, nutritional issues, and assessing bone content.

    As well, Impedimed offers a cloud-based digital platform to manage patient data. The company is based in Australia and generates most of its revenue in North America. 

    IPD Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    19 Jun 2024 $0.07 $0.00 0.00% 1,899,078 $0.07 $0.08 $0.07
    18 Jun 2024 $0.07 $0.00 0.00% 1,414,540 $0.07 $0.07 $0.07
    17 Jun 2024 $0.07 $0.00 0.00% 698,096 $0.07 $0.07 $0.07
    14 Jun 2024 $0.07 $0.00 0.00% 2,117,041 $0.07 $0.07 $0.07
    13 Jun 2024 $0.07 $0.00 0.00% 5,842,526 $0.07 $0.07 $0.06
    12 Jun 2024 $0.07 $0.00 0.00% 3,171,991 $0.07 $0.07 $0.07
    11 Jun 2024 $0.07 $0.00 0.00% 987,023 $0.07 $0.07 $0.07
    07 Jun 2024 $0.07 $0.00 0.00% 1,668,703 $0.07 $0.07 $0.07
    06 Jun 2024 $0.07 $0.00 0.00% 2,115,163 $0.07 $0.07 $0.07
    05 Jun 2024 $0.07 $0.00 0.00% 3,410,713 $0.07 $0.07 $0.07
    04 Jun 2024 $0.07 $0.00 0.00% 1,025,943 $0.08 $0.08 $0.07
    03 Jun 2024 $0.08 $0.00 0.00% 357,296 $0.08 $0.08 $0.08
    31 May 2024 $0.08 $0.00 0.00% 1,863,240 $0.08 $0.08 $0.07
    30 May 2024 $0.08 $0.00 0.00% 827,316 $0.08 $0.08 $0.08
    29 May 2024 $0.08 $0.00 0.00% 981,701 $0.08 $0.08 $0.08
    28 May 2024 $0.08 $0.00 0.00% 906,720 $0.08 $0.08 $0.08
    27 May 2024 $0.08 $0.00 0.00% 1,630,977 $0.08 $0.08 $0.08
    24 May 2024 $0.08 $0.00 0.00% 2,590,373 $0.08 $0.08 $0.08
    23 May 2024 $0.08 $0.00 0.00% 1,059,895 $0.09 $0.09 $0.08
    22 May 2024 $0.08 $0.00 0.00% 348,827 $0.09 $0.09 $0.08
    21 May 2024 $0.09 $0.00 0.00% 578,178 $0.09 $0.09 $0.09

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    14 May 2024 Christine Emmanuel-Donnelly Buy 100,000 $8,000
    On-market trade.
    08 May 2024 Janelle Delaney Buy 634,177 $50,099
    On-market trade.
    06 May 2024 Andrew Grant Buy 100,000 $8,050
    On-market trade.
    25 Mar 2024 Janelle Delaney Buy 568,181 $49,999
    On-market trade.
    22 Mar 2024 Janelle Delaney Buy 581,395 $49,999
    On-market trade.
    04 Mar 2024 Janelle Delaney Buy 1,137,634 $99,591
    On-market trade.
    29 Feb 2024 Andrew Grant Buy 100,000 $87,000
    On-market trade.
    28 Feb 2024 Andrew Grant Buy 130,000 $10,920
    On-market trade.
    28 Feb 2024 Christine Emmanuel-Donnelly Buy 121,952 $10,169
    On-market trade.
    14 Dec 2023 Janelle Delaney Buy 942,232 $135,148
    On-market trade.
    13 Dec 2023 Christine Emmanuel-Donnelly Buy 67,857 $9,499
    On-market trade.
    05 Dec 2023 Janelle Delaney Buy 66,503 $8,977
    On-market trade.
    04 Dec 2023 Andrew Grant Buy 70,000 $9,625
    On-market trade.
    20 Nov 2023 Richard Valencia Expiry 10,000,000 $1,300,000
    Options expired.
    20 Nov 2023 Richard Valencia Expiry 20,000,000 $2,600,000
    As advised by the company. Lapse of Options and Performance Rights
    01 Nov 2023 Christine Emmanuel-Donnelly Buy 100,000 $10,500
    On-market trade.
    03 Jul 2023 Janet West Issued 130,152 $21,605
    Director remuneration.
    03 Jul 2023 David Anderson Issued 81,325 $13,499
    Director remuneration.
    03 Jul 2023 Amit Patel Issued 111,145 $18,450
    Director remuneration.
    03 Jul 2023 Donald (Don) Williams Issued 178,916 $29,700
    Director remuneration.
    20 Jun 2023 David Anderson Buy 920,000 $143,980
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Parmjot Bains Managing DirectorInterim CEO Jan 2024
    Dr Bains is a healthcare executive with experience including strategy, sales & marketing, commercial execution, and change management across the US, Asia, Middle East and Australia. Dr Bains joined Pfizer US in 2015 and since then has held several roles located in the United States, Asia Pacific and Middle East. Most recently, Dr Bains was Pfizers Gulf Cluster Country Manager, responsible for setting commercial strategy, aligning team capabilities, driving private and public reimbursement, accelerating sales & marketing activities and key account management. Dr Bains managed a large team across six countries and six therapeutic areas (including breast cancer). Dr Bains former roles include: joint CEO and Chief Operating Officer at Neuren Pharmaceuticals (ASX: NEU) (developing therapies for brain injury, neurodevelopmental and neurodegenerative disorder); CEO of Perseis Therapeutics, (creating monoclonal antibody candidates against breast cancer targets); manager at McKinsey and Company and medical doctor.
    Mr Andrew John Grant Non-Executive Director Sep 2023
    --
    Mr McGregor Grant Executive ChairmanExecutive DirectorInterim CFO Nov 2023
    --
    Ms Christine Emmanuel-Donnelly Non-Executive Director Sep 2023
    --
    Ms Janelle Delaney Non-Executive Director Sep 2023
    --
    Ms Fiona Bones Non-Executive Director Jun 2024
    Ms Bones is currently VP of Finance, International Controller at Google and has worked at Google for over 20 years. Ms Bones rings global experience in finance, corporate governance, and systems transformation.
    Ms Leanne Ralph Company Secretary Jan 2015
    -
    Timothy Cruickshank Chief Financial Officer
    -
    Shashi Tripathi Chief Operating Officer
    -
    Joann Yao Chief Strategy Officer
    -
    Leanne Ralph Company Secretary
    -
    Dennis Schlaht Senior Vice President R&D and Technology
    -
    Lisa Prom Vice President Sales
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    National Nominees Limited 190,580,959 9.44%
    Citicorp Nominees Pty Limited 176,271,813 8.73%
    J P Morgan Nominees Australia Pty Limited 122,801,902 6.08%
    HSBC Custody Nominees (Australia) Limited 86,660,527 4.29%
    Bnp Paribas Noms Pty Ltd 71,262,491 3.53%
    BNP Paribas Nominees Pty Ltd 56,357,329 2.79%
    HSBC Custody Nominees (Australia) Limited i 47,593,537 2.36%
    HSBC Custody Nominees (Australia) Limited A/C 2 28,525,714 1.42%
    Moore Family Nominee Pty Ltd 22,500,000 1.11%
    Mba Investments Pty Ltd 22,490,990 1.11%
    Mr Hamish Alexander Jones 21,263,705 1.05%
    Mr Gregory Wayne Brown 21,100,000 1.05%
    Sunlora Pty Ltd 19,000,000 0.94%
    Apex Investment Management Pty Limited 17,471,778 0.87%
    BNP Paribas Nominees Pty Ltd i 16,201,010 0.82%
    Pakasoluto Pty Limited 16,011,422 0.79%
    Mr Stephen Edward Mahnken & Mrs Dior Leone Mahnken 16,000,000 0.79%
    Dr Hsien Michael Soo 15,394,710 0.76%
    Bsd Pty Ltd 13,300,000 0.66%
    Mid Dig Investments Pty Ltd 12,970,633 0.64%

    Profile

    since

    Note